Lake Jackson, Texas 77566

  • Cataract Extraction

Purpose:

This study evaluates the safety and effectiveness of a capsular tension ring (CTR) when used during cataract surgery. Capsular Tension Rings are used during intraocular lens implantation to give added support in order to keep the intraocular lens well centered, especially in eyes with weak or partially absent zonules. In many cases, capsular tension rings allow a lens to be successfully implanted into an eye which otherwise could not have supported an intraocular lens.


Study summary:

The clinical study of the CTR-10 and CTR-12 Capsular Tension Rings is to be conducted with the following objectives: 1. Determine the ability of the device to maintain the shape of the capsular bag and therefore keep the intraocular lens centered; 2. Determine post-operative visual acuity of patients receiving the capsular tension ring as a secondary method of determining the efficacy; 3. Describe the occurrence and time course of postoperative complications and adverse reactions for capsular tension ring implant subjects; 4. Describe the occurrence of postoperative complications for the implant group and their relationship to ocular complications. 5. Identify groups within the implant study population that are at "high risk" of particular complications. 6. Collect and analyze against those historical controls published by FDA data on: 1. Overall Visual Acuity 2. Best Case Visual Acuity 3. Cumulative Hyphema 4. Cumulative Macular Edema 5. Cumulative Retinal Detachment 6. Cumulative Pupillary Block 7. Cumulative Lens Dislocation 8. Cumulative Endophthalmitis 9. Cumulative Hypopyon 10. Cumulative Surgical Reintervention 11. Persistent Macular Edema 12. Persistent Corneal Edema 13. Persistent Iritis 14. Persistent Raised IOP Requiring treatment 15. Frequency and degree of posterior capsule opacification The investigational plan for the clinical study of capsular tension rings is designed to satisfy the requirements of the Investigational Device Exemption (IDE) regulations, which require a well-controlled clinical trial with ongoing monitoring to evaluate the safety and efficacy of the intraocular lenses. The study will consist of adult patients who will be enrolled into the study. The results of these implants will be carefully monitored for approximately twelve (12) months.


Criteria:

Inclusion Criteria: - The patient is in good general and ocular health, having a vision-reducing cataract in the intended operative eye. - The intended operative eye has a Snellen best corrected visual of 20/40 or worse for distance or the refraction worsens to this level with glare testing. - The patients' worse seeing Eye is 20/70 or better. - The patient is willing and able to complete all required postoperative visits. - The patient is willing to sign a statement of informed consent. - The patient is at least 21 years old. - The patient requires cataract surgery with IOL implantation. - The patient has observed or suspected weakened, torn, missing or otherwise compromised zonules (torn or missing estimated not to exceed one-third of the capsular bag diameter) due to Pseudoexfoliation Syndrome, Marfans Syndrome, trauma or other zonular compromising condition. - The capsule is intact during insertion. Exclusion Criteria: - Only one functional eye - Capsular bag tearing beyond the point where the surgeon thinks it is in the best interest of the patient to have a capsular ring implanted - Significant zonular didlysis during surgery - Preoperative ocular infection - Ocular inflammation or uveitis - Amblyopia - Aniridia - Congenital cataracts - Cataracts due to rubella - Corneal disease - Diabetes - Preoperative intraocular pressure over 21 mm Hg - Iritis - Iris atrophy - Pseudophakic lens exchange - Microphthalmia - Optic atrophy - Macular degeneration - Retinal detachment - Retinal degeneration - Vitritis - Flat anterior chamber - Other conditions as noted by the surgeon which may compromise the safety of the patient or the accuracy of the study


NCT ID:

NCT02332369


Primary Contact:

Study Director
Mark Robinson
Sponsor/CEO

Barry L Bowyer, MSPH
Phone: 7277930170
Email: barry@eyekonmedical.com


Backup Contact:

Email: Mark@eyekonmedical.com
Mark Robinson
Phone: 7277930170


Location Contact:

Lake Jackson, Texas 77566
United States

Christian Penland
Email: ljm.christianp@gmail.com

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: July 23, 2021

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.